Less Ads, More Data, More Tools Register for FREE

UPDATE 2-AstraZeneca's lung disease treatment gets FDA nod

Fri, 24th Jul 2020 07:31

(Adds background, comment from trial investigator)

By Aakash B

July 24 (Reuters) - The U.S. Food and Drug Administration
approved AstraZeneca's drug to treat patients with a
form of lung disease, the British drugmaker said on Friday.

The drug Breztri Aerosphere is being approved as a
maintenance treatment for patients with chronic obstructive
pulmonary disease (COPD), the third leading cause of death
globally, AstraZeneca said.

Known as "smoker's lung", COPD is a progressively worsening
and potentially deadly condition that affects more than 380
million people worldwide, primarily caused by smoking, but also
by occupational hazards such as air pollution or chemical fumes.

The approval for AstraZeneca comes at a time when the
British drugmaker is seeking to catch up with the runaway
success of rival Glaxosmithkline's Trelegy Ellipta drug.

COPD-related sales of Trelegy Ellipta more than tripled to
518 million pounds last year. Trimbow by Italy's Chiesi is
another competitor in the European market.

Breztri Aerosphere, which is a three-drug inhaler, is
already approved in Japan and China for patients with COPD and
is under regulatory review in the European Union, AstraZeneca
said.

Last month, data from a late-stage trial showed that Breztri
reduced the risk of a recurrence in flare-ups, or
exacerbations, by between 13% and 24% when compared to standard
two-drug inhalers, and cut the risk of death from all causes by
46%.

"Preventing exacerbations is central to the management of
COPD ... Breztri Aerosphere has demonstrated significant
benefits in reducing exacerbations," Weill Cornell, an
investigator in a late-stage trial that tested the drug, said.

Sales of Astra's respiratory drugs rose 10% last year, while
oncology drugs saw a 44% surge in revenues.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by
Shounak Dasgupta and Catherine Evans)

Related Shares

More News
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Frid...

31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on ...

30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer resp...

30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.